A Phase 3 Randomized, Multicenter, Double-Blind Study to Evaluate the Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Subjects in Japan With Moderate to Severe Atopic Dermatitis
Phase of Trial: Phase III
Latest Information Update: 21 Feb 2019
At a glance
- Drugs Upadacitinib (Primary) ; Corticosteroids
- Indications Atopic dermatitis
- Focus Adverse reactions; Registrational
- Sponsors AbbVie
- 11 Feb 2019 Planned End Date changed from 8 May 2022 to 21 Feb 2022.
- 19 Nov 2018 Planned End Date changed from 8 Jun 2022 to 8 May 2022.
- 19 Nov 2018 Planned primary completion date changed from 21 Dec 2019 to 14 Feb 2020.